USA flag logo/image

An Official Website of the United States Government

A2a Adenosine Blockers for Parkinson's Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76381
Program Year/Program:
2005 / STTR
Agency Tracking Number:
NS051025
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE SUITE 201 CHARLOTTESVILLE, VA 22902
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: A2a Adenosine Blockers for Parkinson's Disease
Agency: HHS
Contract: 1R41NS051025-01
Award Amount: $139,176.00
 

Abstract:

DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to be considered clinical candidates. This proposal is a phase I SBIR to investigate proprietary novel potent, selective and bioavailable AM blockers for the treatment of PD. It is collaboration between Adenosine Therapeutics, LLC, where medicinal chemistry and compound characterization are conducted, and the Boston University laboratory of Dr. Jiang-Fan Chen, where compounds are investigated in several mouse models of PD. We have already identified one compound, ATL-444, that is very effective in stimulating locomotor activity in a mouse model that is highly predictive of efficacy in PD. There are two specific aims: Aim 1 - Identify another compound, in addition to ATL-444, that is a therapeutic candidate for PD. For this aim, additional compounds will be synthesized and screened, first in radioligand binding assays, and subsequently for locomotor activity in mice. ATL-444 and 1 additional compound will be selected for detailed evaluation in aim 2. Aim 2- Evaluate novel A2A antagonists in four mouse models of PD. These include: A) motor function in normal and dopamine-depleted mice; B) synergistic activity with L-dopa to stimulate motor activity in dopamine-depleted mice; C) attenuation MPTP-induced neurotoxicity by inhibiting MPTP metabolism; and D) delayed L-dopa-induced locomotor sensitization in unilateral 6-OHDA-lesioned mice. We anticipate that we will identify 1 or 2 new clinical candidates for the treatment of PD. Our long-term goal is to bring a new compound into clinical trials. Such a new compound has high therapeutic significance and would be of high commercial value.

Principal Investigator:

Robert D. Thompson
4349519484
RDT@ADENRX.COM

Business Contact:


4342209400
Small Business Information at Submission:

Adenosine Therapeutics, LLC
310 Fourth Street Ne, Suite 201 Charlottesville, VA 22902

EIN/Tax ID: 541932209
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
BOSTON UNIVERSITY SCHOOL OF MEDICINE
BOYS TOWN NATIONAL RESEARCH HOSP
555 N 30TH ST
OMAHA, NE 68131
RI Type: Domestic nonprofit research organization